Mechanisms underlying dose-limiting toxicities of conventional chemotherapeutic agents

• Published in: Journal of chemotherapy (Florence) p. 1
• Main Authors: Manavi, Mohammad Amin, Fathian Nasab, Mohammad Hosein, Mohammad Jafari, Razieh, Dehpour, Ahmad Reza
• Format: Journal Article
• Language: English
• Published: England 05.01.2024
• Subjects: cardiotoxicity; maximum tolerated dose; dose-limiting toxicity; nephrotoxicity; hepatotoxicity; Anti-cancer drugs; pulmonary fibrosis; oxidative stress
• ISSN: 1973-9478
• DOI: 10.1080/1120009X.2023.2300217

Dose-limiting toxicities (DLTs) are severe adverse effects that define the maximum tolerated dose of a cancer drug. In addition to the specific mechanisms of each drug, common contributing factors include inflammation, apoptosis, ion imbalances, and tissue-specific enzyme deficiencies. Among various DLTs are bleomycin-induced pulmonary fibrosis, doxorubicin-induced cardiomyopathy, cisplatin-induced nephrotoxicity, methotrexate-induced hepatotoxicity, vincristine-induced neurotoxicity, paclitaxel-induced peripheral neuropathy, and irinotecan, which elicits severe diarrhea. Currently, specific treatments beyond dose reduction are lacking for most toxicities. Further research on cellular and molecular pathways is imperative to improve their management. This review synthesizes preclinical and clinical data on the pharmacological mechanisms underlying DLTs and explores possible treatment approaches. A comprehensive perspective reveals knowledge gaps and emphasizes the need for future studies to develop more targeted strategies for mitigating these dose-dependent adverse effects. This could allow the safer administration of fully efficacious doses to maximize patient survival.